German biotechnology firm sphingotec has collaborated with US-based non-profit organisation Mayo Clinic to investigate the use of its biomarkers for the diagnosis of certain diseases, including those related to kidney, heart, breast cancer and sepsis.
The partnership involves evaluation of biomarkers proenkephalin (penKid), proneurotensin (pro-NT), adrenomedullin (bio-ADM), and high-sensitivity growth hormone (vr-hGH).
penKid is a blood-based biomarker designed to assess the status of kidney function to identify worsening or improvement, primarily in critically ill patients.
sphingotec founder Andreas Bergmann said: “Biomarkers like penKid provide the potential to guide treatment and help patients at an increased risk of kidney failure.
“This collaboration with Mayo Clinic will help provide research and diagnostics for all four assays that we hope will aid in curing, and ultimately preventing, life-threatening diseases.”
pro-NT is being developed for evaluation of breast cancer development risk, bio-ADM could predict shock in patients having sepsis and vr-hGH is intended for cardiovascular disease prediction in men.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The organisations are inviting researchers from other institutions to use these biomarkers in their studies.
Mayo Clinic Cardiovascular Laboratory Medicine clinical chemist and co-director Leslie Donato said: “With this collaboration, Mayo Clinic can serve as a US-based testing centre for any physician or scientist interested in evaluating these assays for their own research questions.
“We can run their samples on these analytically validated tests, and together, we can help determine the clinical utility for these biomarkers, ultimately better serving all of our patients.”